Kathryn Hassell
Concepts (534)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 45 | 2025 | 268 | 6.870 |
Why?
| | Water Pollutants, Chemical | 13 | 2022 | 217 | 2.210 |
Why?
| | Antiphospholipid Syndrome | 5 | 2023 | 33 | 1.770 |
Why?
| | Migraine Disorders | 2 | 2023 | 105 | 1.320 |
Why?
| | Anticoagulants | 8 | 2021 | 669 | 1.190 |
Why?
| | Perciformes | 5 | 2018 | 19 | 1.150 |
Why?
| | Heparin | 5 | 2011 | 262 | 1.100 |
Why?
| | Thrombocytopenia | 5 | 2014 | 205 | 1.090 |
Why?
| | Antibodies, Antiphospholipid | 4 | 2023 | 25 | 1.040 |
Why?
| | Fishes | 4 | 2021 | 111 | 1.030 |
Why?
| | Estrogens | 3 | 2016 | 369 | 0.800 |
Why?
| | Hydroxyurea | 5 | 2016 | 36 | 0.780 |
Why?
| | Hypertension, Pulmonary | 11 | 2025 | 1924 | 0.760 |
Why?
| | Pyridones | 2 | 2021 | 170 | 0.730 |
Why?
| | Blood Transfusion | 7 | 2015 | 350 | 0.710 |
Why?
| | Disorders of Sex Development | 2 | 2018 | 39 | 0.690 |
Why?
| | Hirudins | 4 | 2011 | 52 | 0.670 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2023 | 239 | 0.660 |
Why?
| | Hemoglobins | 8 | 2021 | 357 | 0.650 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 278 | 0.650 |
Why?
| | Testis | 2 | 2018 | 157 | 0.650 |
Why?
| | Pyrazoles | 2 | 2021 | 429 | 0.640 |
Why?
| | Caprylates | 1 | 2020 | 25 | 0.640 |
Why?
| | Alkanesulfonic Acids | 1 | 2020 | 41 | 0.620 |
Why?
| | Environmental Monitoring | 8 | 2025 | 366 | 0.610 |
Why?
| | Oocytes | 2 | 2021 | 179 | 0.580 |
Why?
| | Quality of Life | 6 | 2017 | 2954 | 0.570 |
Why?
| | Fluorocarbons | 1 | 2020 | 116 | 0.560 |
Why?
| | Neonatal Screening | 3 | 2020 | 167 | 0.540 |
Why?
| | Hemopexin | 3 | 2025 | 29 | 0.540 |
Why?
| | Cyprinidae | 1 | 2016 | 21 | 0.500 |
Why?
| | Pain | 5 | 2023 | 780 | 0.490 |
Why?
| | Australia | 10 | 2022 | 304 | 0.490 |
Why?
| | beta-Thalassemia | 2 | 2025 | 36 | 0.420 |
Why?
| | Pain Measurement | 3 | 2017 | 548 | 0.420 |
Why?
| | Embryo, Nonmammalian | 2 | 2019 | 169 | 0.420 |
Why?
| | Surveys and Questionnaires | 4 | 2017 | 5892 | 0.410 |
Why?
| | Health Status Indicators | 1 | 2014 | 165 | 0.410 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.400 |
Why?
| | Tricuspid Valve Insufficiency | 3 | 2011 | 24 | 0.380 |
Why?
| | Adult | 41 | 2025 | 38389 | 0.380 |
Why?
| | Humans | 76 | 2025 | 139062 | 0.380 |
Why?
| | Peptide Fragments | 4 | 2014 | 695 | 0.370 |
Why?
| | Antithrombins | 2 | 2011 | 62 | 0.350 |
Why?
| | Sewage | 2 | 2025 | 32 | 0.350 |
Why?
| | Thrombosis | 4 | 2021 | 383 | 0.350 |
Why?
| | Empirical Research | 1 | 2011 | 22 | 0.350 |
Why?
| | Male | 47 | 2025 | 68324 | 0.330 |
Why?
| | Nomograms | 1 | 2011 | 55 | 0.330 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 740 | 0.320 |
Why?
| | Censuses | 1 | 2010 | 35 | 0.320 |
Why?
| | Endocrine Disruptors | 3 | 2016 | 43 | 0.320 |
Why?
| | Animals | 28 | 2025 | 37351 | 0.320 |
Why?
| | Female | 43 | 2025 | 74074 | 0.310 |
Why?
| | Rivaroxaban | 2 | 2025 | 256 | 0.310 |
Why?
| | Vitellogenins | 3 | 2016 | 11 | 0.300 |
Why?
| | Heme | 3 | 2025 | 77 | 0.300 |
Why?
| | Venous Thromboembolism | 2 | 2025 | 324 | 0.300 |
Why?
| | Young Adult | 18 | 2025 | 13341 | 0.290 |
Why?
| | Thrombophilia | 3 | 2007 | 86 | 0.290 |
Why?
| | Health Priorities | 1 | 2009 | 44 | 0.290 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2008 | 13 | 0.280 |
Why?
| | Estuaries | 2 | 2021 | 2 | 0.280 |
Why?
| | Stroke | 3 | 2021 | 1138 | 0.270 |
Why?
| | Self Care | 1 | 2010 | 383 | 0.270 |
Why?
| | Gonads | 2 | 2018 | 22 | 0.270 |
Why?
| | Heart Septal Defects, Atrial | 2 | 2005 | 58 | 0.270 |
Why?
| | Population Surveillance | 2 | 2010 | 480 | 0.270 |
Why?
| | Nitric Oxide | 2 | 2018 | 895 | 0.260 |
Why?
| | Sickle Cell Trait | 2 | 2018 | 13 | 0.260 |
Why?
| | Middle Aged | 25 | 2025 | 33864 | 0.260 |
Why?
| | Hospitalists | 1 | 2011 | 247 | 0.260 |
Why?
| | Fresh Water | 3 | 2020 | 57 | 0.260 |
Why?
| | Haptoglobins | 2 | 2018 | 54 | 0.250 |
Why?
| | Biodiversity | 2 | 2021 | 415 | 0.250 |
Why?
| | Kinetics | 2 | 2020 | 1656 | 0.250 |
Why?
| | Insecta | 1 | 2006 | 70 | 0.250 |
Why?
| | Phospholipids | 1 | 2008 | 219 | 0.250 |
Why?
| | Estradiol | 4 | 2016 | 525 | 0.240 |
Why?
| | Environmental Pollutants | 2 | 2019 | 160 | 0.240 |
Why?
| | Fats | 1 | 2025 | 18 | 0.240 |
Why?
| | Patient Education as Topic | 1 | 2010 | 763 | 0.240 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 25 | 0.240 |
Why?
| | Health Services Accessibility | 3 | 2016 | 1005 | 0.230 |
Why?
| | Adolescent | 20 | 2025 | 21561 | 0.230 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2025 | 661 | 0.230 |
Why?
| | Iron | 3 | 2025 | 324 | 0.230 |
Why?
| | Hospitalization | 4 | 2025 | 2223 | 0.220 |
Why?
| | Estrone | 2 | 2016 | 36 | 0.220 |
Why?
| | Spleen | 2 | 2025 | 524 | 0.220 |
Why?
| | Factor Xa Inhibitors | 1 | 2025 | 172 | 0.200 |
Why?
| | Hypertrichosis | 1 | 2023 | 8 | 0.200 |
Why?
| | Hemoglobinopathies | 1 | 2023 | 5 | 0.200 |
Why?
| | Cadmium | 2 | 2021 | 69 | 0.200 |
Why?
| | Headache | 2 | 2023 | 147 | 0.200 |
Why?
| | Acromegaly | 1 | 2023 | 16 | 0.200 |
Why?
| | Antisickling Agents | 2 | 2016 | 7 | 0.200 |
Why?
| | Hemostasis | 2 | 2007 | 87 | 0.200 |
Why?
| | Wetlands | 2 | 2022 | 30 | 0.200 |
Why?
| | Limb Deformities, Congenital | 1 | 2023 | 21 | 0.200 |
Why?
| | Child | 20 | 2024 | 21906 | 0.190 |
Why?
| | Lung | 3 | 2025 | 4094 | 0.190 |
Why?
| | Bays | 3 | 2017 | 7 | 0.190 |
Why?
| | Psychometrics | 3 | 2016 | 729 | 0.190 |
Why?
| | Mass Screening | 1 | 2011 | 1287 | 0.190 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2864 | 0.190 |
Why?
| | Pesticides | 1 | 2022 | 62 | 0.190 |
Why?
| | Volatile Organic Compounds | 1 | 2023 | 61 | 0.190 |
Why?
| | Recombinant Proteins | 4 | 2011 | 1361 | 0.190 |
Why?
| | Hemolysis | 4 | 2021 | 202 | 0.180 |
Why?
| | Arginine | 2 | 2015 | 261 | 0.180 |
Why?
| | Metallothionein | 1 | 2021 | 25 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2021 | 85 | 0.170 |
Why?
| | alpha-Thalassemia | 1 | 2020 | 5 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2021 | 84 | 0.170 |
Why?
| | Acute Pain | 1 | 2021 | 50 | 0.170 |
Why?
| | Desogestrel | 1 | 2021 | 46 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2023 | 148 | 0.170 |
Why?
| | Fertility Preservation | 1 | 2021 | 52 | 0.170 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2021 | 66 | 0.160 |
Why?
| | Proteome | 1 | 2025 | 472 | 0.160 |
Why?
| | Infertility, Female | 1 | 2021 | 109 | 0.160 |
Why?
| | Vascular Remodeling | 2 | 2019 | 192 | 0.160 |
Why?
| | Ecotoxicology | 1 | 2019 | 3 | 0.160 |
Why?
| | Partial Thromboplastin Time | 2 | 2011 | 54 | 0.160 |
Why?
| | Aged | 11 | 2025 | 24236 | 0.160 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 27 | 0.160 |
Why?
| | Clove Oil | 1 | 2019 | 1 | 0.160 |
Why?
| | Eugenol | 1 | 2019 | 4 | 0.160 |
Why?
| | Iron Chelating Agents | 2 | 2011 | 19 | 0.150 |
Why?
| | Cyprinodontiformes | 1 | 2019 | 5 | 0.150 |
Why?
| | Multiple Organ Failure | 2 | 2005 | 123 | 0.150 |
Why?
| | Hemorrhage | 2 | 2021 | 732 | 0.150 |
Why?
| | Iron Overload | 2 | 2011 | 17 | 0.150 |
Why?
| | Benzoates | 2 | 2011 | 46 | 0.150 |
Why?
| | Practice Guidelines as Topic | 4 | 2015 | 1550 | 0.150 |
Why?
| | Prospective Studies | 9 | 2025 | 7660 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2011 | 278 | 0.150 |
Why?
| | Liver | 3 | 2025 | 1882 | 0.150 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.150 |
Why?
| | Plastics | 1 | 2019 | 50 | 0.150 |
Why?
| | Altitude | 3 | 2018 | 467 | 0.150 |
Why?
| | Signal Transduction | 2 | 2013 | 5094 | 0.140 |
Why?
| | Reproducibility of Results | 3 | 2017 | 3316 | 0.140 |
Why?
| | Anesthetics | 1 | 2019 | 98 | 0.140 |
Why?
| | Lipids | 2 | 2023 | 676 | 0.140 |
Why?
| | Triazoles | 2 | 2011 | 156 | 0.140 |
Why?
| | Europe | 2 | 2016 | 407 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2019 | 291 | 0.140 |
Why?
| | Aspirin | 1 | 2021 | 391 | 0.140 |
Why?
| | Surgical Procedures, Operative | 2 | 2014 | 263 | 0.140 |
Why?
| | Lipoproteins | 1 | 2018 | 160 | 0.130 |
Why?
| | Climate Change | 1 | 2019 | 175 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 209 | 0.130 |
Why?
| | Factor Analysis, Statistical | 2 | 2016 | 294 | 0.130 |
Why?
| | Prevalence | 4 | 2024 | 2746 | 0.130 |
Why?
| | Cohort Studies | 7 | 2018 | 5736 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2025 | 10961 | 0.130 |
Why?
| | Pulmonary Artery | 4 | 2019 | 1108 | 0.130 |
Why?
| | Platelet Factor 4 | 2 | 2008 | 35 | 0.130 |
Why?
| | Toll-Like Receptor 9 | 1 | 2017 | 33 | 0.130 |
Why?
| | Zinc | 1 | 2020 | 299 | 0.130 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 252 | 0.130 |
Why?
| | United States | 11 | 2023 | 15065 | 0.130 |
Why?
| | Hypoxia | 3 | 2019 | 1146 | 0.130 |
Why?
| | Osmeriformes | 1 | 2016 | 1 | 0.130 |
Why?
| | Carps | 1 | 2016 | 4 | 0.130 |
Why?
| | Phenylketonurias | 1 | 2016 | 15 | 0.120 |
Why?
| | Heart Diseases | 1 | 2019 | 336 | 0.120 |
Why?
| | Asia | 1 | 2016 | 70 | 0.120 |
Why?
| | Principal Component Analysis | 2 | 2016 | 192 | 0.120 |
Why?
| | Olfactory Perception | 1 | 2016 | 16 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2019 | 621 | 0.120 |
Why?
| | Employment | 2 | 2014 | 183 | 0.120 |
Why?
| | Metals, Heavy | 1 | 2016 | 31 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 816 | 0.120 |
Why?
| | Rivers | 1 | 2016 | 64 | 0.120 |
Why?
| | Erythrocyte Transfusion | 2 | 2015 | 200 | 0.120 |
Why?
| | Trace Elements | 1 | 2016 | 51 | 0.120 |
Why?
| | Infant, Newborn | 5 | 2024 | 6152 | 0.120 |
Why?
| | Macrophages | 2 | 2023 | 1545 | 0.120 |
Why?
| | Anesthesia | 1 | 2019 | 247 | 0.120 |
Why?
| | Copper | 1 | 2016 | 110 | 0.120 |
Why?
| | Retrospective Studies | 8 | 2021 | 15922 | 0.120 |
Why?
| | Thalassemia | 1 | 2015 | 7 | 0.120 |
Why?
| | Lung Diseases | 2 | 2019 | 783 | 0.120 |
Why?
| | North America | 1 | 2016 | 311 | 0.120 |
Why?
| | Splenic Infarction | 1 | 2014 | 1 | 0.110 |
Why?
| | Fatigue | 1 | 2017 | 337 | 0.110 |
Why?
| | Protein S Deficiency | 1 | 1994 | 7 | 0.110 |
Why?
| | Zebrafish | 1 | 2019 | 501 | 0.110 |
Why?
| | Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| | Blood Component Removal | 1 | 2014 | 27 | 0.110 |
Why?
| | Complement Inactivator Proteins | 1 | 1994 | 42 | 0.110 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 183 | 0.110 |
Why?
| | Quality of Health Care | 2 | 2016 | 654 | 0.110 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 107 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 88 | 0.100 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4339 | 0.100 |
Why?
| | Thromboembolism | 1 | 2014 | 118 | 0.100 |
Why?
| | Biomarkers | 5 | 2017 | 4115 | 0.100 |
Why?
| | Leg Ulcer | 1 | 2013 | 4 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5813 | 0.100 |
Why?
| | Larva | 2 | 2019 | 235 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2014 | 416 | 0.100 |
Why?
| | Ethinyl Estradiol | 1 | 2012 | 15 | 0.100 |
Why?
| | Thrombin | 2 | 2023 | 158 | 0.100 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 105 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 856 | 0.100 |
Why?
| | Venous Thrombosis | 2 | 2005 | 189 | 0.100 |
Why?
| | Neoplasms | 2 | 2021 | 2703 | 0.100 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 408 | 0.100 |
Why?
| | Sex Factors | 3 | 2019 | 2054 | 0.100 |
Why?
| | Societies, Medical | 1 | 2017 | 839 | 0.090 |
Why?
| | Testosterone | 1 | 2016 | 402 | 0.090 |
Why?
| | Chronic Pain | 1 | 2017 | 272 | 0.090 |
Why?
| | Racism | 1 | 2014 | 145 | 0.090 |
Why?
| | Preoperative Care | 2 | 2005 | 368 | 0.090 |
Why?
| | Pharmacists | 1 | 2014 | 262 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 934 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2016 | 575 | 0.090 |
Why?
| | Hemoglobin SC Disease | 3 | 1998 | 14 | 0.090 |
Why?
| | Prostheses and Implants | 2 | 2021 | 143 | 0.090 |
Why?
| | Child, Preschool | 10 | 2024 | 11142 | 0.090 |
Why?
| | Analgesics, Opioid | 3 | 2023 | 1090 | 0.090 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 560 | 0.090 |
Why?
| | Mortality | 2 | 2012 | 360 | 0.090 |
Why?
| | Creatinine | 2 | 2014 | 489 | 0.090 |
Why?
| | Pipecolic Acids | 1 | 2011 | 26 | 0.090 |
Why?
| | Transfusion Reaction | 1 | 2011 | 62 | 0.080 |
Why?
| | Hemofiltration | 1 | 2010 | 23 | 0.080 |
Why?
| | Mice | 6 | 2025 | 17867 | 0.080 |
Why?
| | Sulfones | 1 | 2011 | 110 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2013 | 612 | 0.080 |
Why?
| | Awareness | 1 | 2010 | 102 | 0.080 |
Why?
| | Disease Progression | 4 | 2023 | 2741 | 0.080 |
Why?
| | Disease Management | 2 | 2011 | 620 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2011 | 329 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2051 | 0.080 |
Why?
| | Piperazines | 1 | 2011 | 349 | 0.070 |
Why?
| | United Kingdom | 3 | 2014 | 321 | 0.070 |
Why?
| | Echocardiography | 1 | 2011 | 639 | 0.070 |
Why?
| | Career Choice | 1 | 2010 | 232 | 0.070 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 362 | 0.070 |
Why?
| | Drug Utilization Review | 1 | 2008 | 58 | 0.070 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2008 | 86 | 0.070 |
Why?
| | Seawater | 1 | 2008 | 31 | 0.070 |
Why?
| | Anaerobiosis | 1 | 2008 | 65 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2008 | 159 | 0.070 |
Why?
| | Pregnancy | 3 | 2005 | 6874 | 0.070 |
Why?
| | Endothelial Cells | 1 | 2013 | 794 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2025 | 7698 | 0.070 |
Why?
| | Software | 1 | 2013 | 668 | 0.070 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1079 | 0.070 |
Why?
| | Cost of Illness | 1 | 2010 | 308 | 0.070 |
Why?
| | Depression | 1 | 2017 | 1467 | 0.070 |
Why?
| | Community Participation | 1 | 2009 | 132 | 0.070 |
Why?
| | Metabolomics | 1 | 2013 | 692 | 0.070 |
Why?
| | Body Size | 1 | 2008 | 103 | 0.070 |
Why?
| | Proteomics | 2 | 2025 | 1114 | 0.070 |
Why?
| | Lipid Peroxidation | 2 | 2018 | 152 | 0.070 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 125 | 0.070 |
Why?
| | Deferoxamine | 1 | 2007 | 26 | 0.070 |
Why?
| | Sulfonamides | 1 | 2011 | 511 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2023 | 1946 | 0.070 |
Why?
| | Chironomidae | 1 | 2006 | 1 | 0.060 |
Why?
| | Registries | 2 | 2023 | 2054 | 0.060 |
Why?
| | Age Factors | 2 | 2014 | 3273 | 0.060 |
Why?
| | Acute Kidney Injury | 2 | 2010 | 815 | 0.060 |
Why?
| | Algorithms | 1 | 2014 | 1722 | 0.060 |
Why?
| | Environmental Exposure | 3 | 2019 | 568 | 0.060 |
Why?
| | Rhabdomyolysis | 2 | 2018 | 24 | 0.060 |
Why?
| | Urbanization | 2 | 2016 | 28 | 0.060 |
Why?
| | Social Support | 1 | 2010 | 628 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6885 | 0.060 |
Why?
| | Fibrinolysis | 2 | 1998 | 147 | 0.060 |
Why?
| | Body Weight | 2 | 2021 | 995 | 0.060 |
Why?
| | Coronary Angiography | 1 | 2008 | 321 | 0.060 |
Why?
| | Oils | 1 | 2025 | 21 | 0.060 |
Why?
| | Dermatan Sulfate | 1 | 2005 | 4 | 0.060 |
Why?
| | Health Care Surveys | 2 | 2020 | 565 | 0.060 |
Why?
| | Species Specificity | 1 | 2006 | 583 | 0.060 |
Why?
| | Factor V | 1 | 2005 | 24 | 0.060 |
Why?
| | Captopril | 1 | 2005 | 12 | 0.060 |
Why?
| | Waste Disposal, Fluid | 1 | 2025 | 51 | 0.060 |
Why?
| | Heparitin Sulfate | 1 | 2005 | 46 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 31 | 0.060 |
Why?
| | Ecosystem | 2 | 2021 | 578 | 0.060 |
Why?
| | Heme Oxygenase-1 | 1 | 2025 | 65 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1313 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2016 | 2106 | 0.060 |
Why?
| | Angina, Unstable | 1 | 2005 | 78 | 0.060 |
Why?
| | Infant Mortality | 1 | 2005 | 116 | 0.060 |
Why?
| | Polysaccharides | 1 | 2005 | 87 | 0.050 |
Why?
| | Standard of Care | 1 | 2025 | 78 | 0.050 |
Why?
| | Risk | 2 | 2005 | 913 | 0.050 |
Why?
| | Public Health Surveillance | 1 | 2024 | 84 | 0.050 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2005 | 80 | 0.050 |
Why?
| | Needs Assessment | 1 | 2007 | 381 | 0.050 |
Why?
| | Chest Pain | 1 | 2005 | 96 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2005 | 87 | 0.050 |
Why?
| | Immunoglobulin G | 1 | 2008 | 904 | 0.050 |
Why?
| | Aerosols | 1 | 2025 | 181 | 0.050 |
Why?
| | Drug Combinations | 1 | 2005 | 347 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 2 | 2013 | 1315 | 0.050 |
Why?
| | Alabama | 1 | 2023 | 31 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5165 | 0.050 |
Why?
| | Acute Disease | 2 | 2019 | 1011 | 0.050 |
Why?
| | Syndrome | 2 | 2014 | 379 | 0.050 |
Why?
| | Risk Factors | 5 | 2018 | 10426 | 0.050 |
Why?
| | Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 321 | 0.050 |
Why?
| | E-Selectin | 1 | 2023 | 57 | 0.050 |
Why?
| | Oxygen | 1 | 2008 | 976 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 408 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 163 | 0.050 |
Why?
| | Medical Records | 1 | 2023 | 184 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 495 | 0.050 |
Why?
| | Healthcare Disparities | 1 | 2009 | 661 | 0.050 |
Why?
| | Coronary Artery Disease | 1 | 2008 | 701 | 0.050 |
Why?
| | Substance-Related Disorders | 1 | 2011 | 1083 | 0.050 |
Why?
| | P-Selectin | 1 | 2021 | 28 | 0.050 |
Why?
| | Agriculture | 1 | 2022 | 101 | 0.050 |
Why?
| | Data Collection | 1 | 2024 | 663 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2025 | 582 | 0.040 |
Why?
| | Colorado | 3 | 2024 | 4532 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2836 | 0.040 |
Why?
| | Blood Pressure | 3 | 2018 | 1735 | 0.040 |
Why?
| | Dietary Exposure | 1 | 2021 | 6 | 0.040 |
Why?
| | Vitrification | 1 | 2021 | 6 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2021 | 12 | 0.040 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2021 | 7 | 0.040 |
Why?
| | Oogenesis | 1 | 2021 | 19 | 0.040 |
Why?
| | Phylogeography | 1 | 2021 | 59 | 0.040 |
Why?
| | Ovulation Induction | 1 | 2021 | 58 | 0.040 |
Why?
| | von Willebrand Factor | 2 | 1998 | 81 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 58 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 571 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2016 | 1498 | 0.040 |
Why?
| | Monocytes | 1 | 2023 | 573 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2004 | 527 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 183 | 0.040 |
Why?
| | Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| | Cryopreservation | 1 | 2021 | 104 | 0.040 |
Why?
| | Metals | 1 | 2021 | 140 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 243 | 0.040 |
Why?
| | HIV Infections | 1 | 1994 | 2946 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2021 | 212 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 81 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2018 | 3584 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2005 | 1516 | 0.040 |
Why?
| | Rats | 2 | 2019 | 5598 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 333 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2876 | 0.040 |
Why?
| | Proteinuria | 1 | 2018 | 97 | 0.040 |
Why?
| | Endothelins | 1 | 2018 | 63 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 145 | 0.040 |
Why?
| | Thrombomodulin | 1 | 1998 | 10 | 0.040 |
Why?
| | Guinea Pigs | 1 | 2018 | 171 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2025 | 1327 | 0.040 |
Why?
| | Body Height | 1 | 2018 | 196 | 0.030 |
Why?
| | Victoria | 1 | 2017 | 18 | 0.030 |
Why?
| | Public Health Practice | 1 | 2017 | 68 | 0.030 |
Why?
| | Anemia, Hemolytic | 1 | 2017 | 20 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2011 | 769 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 704 | 0.030 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2016 | 9 | 0.030 |
Why?
| | Fish Proteins | 1 | 2016 | 10 | 0.030 |
Why?
| | Bile | 1 | 2016 | 25 | 0.030 |
Why?
| | Pilot Projects | 2 | 2016 | 1763 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 171 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1036 | 0.030 |
Why?
| | Public-Private Sector Partnerships | 1 | 2017 | 44 | 0.030 |
Why?
| | Proteins | 1 | 2023 | 1014 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1998 | 148 | 0.030 |
Why?
| | Polychlorinated Biphenyls | 1 | 2016 | 12 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 56 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 5537 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 345 | 0.030 |
Why?
| | Community Health Services | 1 | 2017 | 225 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2017 | 203 | 0.030 |
Why?
| | Odorants | 1 | 2016 | 111 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2013 | 2822 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 3651 | 0.030 |
Why?
| | Mononuclear Phagocyte System | 1 | 1995 | 12 | 0.030 |
Why?
| | Erythrocyte Count | 1 | 1995 | 21 | 0.030 |
Why?
| | Erythrocytes, Abnormal | 1 | 1995 | 12 | 0.030 |
Why?
| | Arginase | 1 | 2015 | 28 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 2016 | 115 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 284 | 0.030 |
Why?
| | Vitamin B 6 Deficiency | 1 | 1994 | 6 | 0.030 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| | Amino Acids, Sulfur | 1 | 1994 | 8 | 0.030 |
Why?
| | Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| | beta 2-Glycoprotein I | 1 | 1994 | 6 | 0.030 |
Why?
| | Lupus Coagulation Inhibitor | 1 | 1994 | 7 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2014 | 54 | 0.030 |
Why?
| | Siblings | 1 | 2015 | 216 | 0.030 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2014 | 33 | 0.030 |
Why?
| | Antibodies, Anticardiolipin | 1 | 1994 | 11 | 0.030 |
Why?
| | Blood Coagulation | 1 | 1996 | 265 | 0.030 |
Why?
| | Hematocrit | 1 | 2014 | 104 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 142 | 0.030 |
Why?
| | Interview, Psychological | 1 | 2014 | 95 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 111 | 0.030 |
Why?
| | Automation | 1 | 2014 | 97 | 0.030 |
Why?
| | Folic Acid Deficiency | 1 | 1994 | 49 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2015 | 145 | 0.030 |
Why?
| | Penicillins | 1 | 2014 | 58 | 0.030 |
Why?
| | Blood Platelets | 1 | 1998 | 426 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 67 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 396 | 0.030 |
Why?
| | Vitamin B 12 Deficiency | 1 | 1994 | 81 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1935 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 449 | 0.030 |
Why?
| | Hematologic Tests | 1 | 1994 | 21 | 0.030 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 87 | 0.030 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2014 | 98 | 0.030 |
Why?
| | Homocysteine | 1 | 1994 | 160 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 424 | 0.030 |
Why?
| | Ownership | 1 | 2014 | 98 | 0.030 |
Why?
| | Personnel Selection | 1 | 2014 | 81 | 0.030 |
Why?
| | Smegmamorpha | 1 | 2013 | 6 | 0.030 |
Why?
| | Folic Acid | 1 | 1995 | 188 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2015 | 365 | 0.030 |
Why?
| | Carrier Proteins | 2 | 1995 | 739 | 0.030 |
Why?
| | Catalase | 1 | 2013 | 134 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 82 | 0.030 |
Why?
| | Mood Disorders | 1 | 2014 | 135 | 0.030 |
Why?
| | Abdominal Pain | 1 | 2014 | 146 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1994 | 65 | 0.030 |
Why?
| | Hemoglobin, Sickle | 1 | 2013 | 18 | 0.030 |
Why?
| | Antibiotic Prophylaxis | 1 | 2014 | 122 | 0.030 |
Why?
| | Professional Role | 1 | 2014 | 167 | 0.030 |
Why?
| | Permeability | 1 | 2013 | 161 | 0.030 |
Why?
| | Brain Diseases | 1 | 1994 | 148 | 0.030 |
Why?
| | Cysteine | 1 | 1994 | 204 | 0.020 |
Why?
| | Methylamines | 1 | 2013 | 34 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2014 | 274 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 520 | 0.020 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 30 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2016 | 512 | 0.020 |
Why?
| | Minority Groups | 1 | 2014 | 274 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 394 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 786 | 0.020 |
Why?
| | Glycoproteins | 1 | 1994 | 359 | 0.020 |
Why?
| | Perioperative Care | 1 | 2014 | 214 | 0.020 |
Why?
| | Vascular Diseases | 1 | 2015 | 242 | 0.020 |
Why?
| | Choline | 1 | 2013 | 131 | 0.020 |
Why?
| | Social Behavior | 1 | 2014 | 291 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 903 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2008 | 3629 | 0.020 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 286 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 247 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 398 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2858 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 72 | 0.020 |
Why?
| | Physician-Patient Relations | 1 | 2016 | 582 | 0.020 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 275 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2014 | 308 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 353 | 0.020 |
Why?
| | Wounds and Injuries | 1 | 2018 | 781 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2011 | 59 | 0.020 |
Why?
| | Health Status | 1 | 2016 | 821 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 203 | 0.020 |
Why?
| | Public Health | 1 | 2016 | 582 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1286 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 198 | 0.020 |
Why?
| | Hemodynamics | 2 | 2011 | 1093 | 0.020 |
Why?
| | Up-Regulation | 1 | 2013 | 854 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 1994 | 328 | 0.020 |
Why?
| | Purines | 1 | 2011 | 180 | 0.020 |
Why?
| | Communication | 1 | 2016 | 932 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2017 | 3038 | 0.020 |
Why?
| | Metabolome | 1 | 2013 | 354 | 0.020 |
Why?
| | NF-kappa B | 1 | 2013 | 680 | 0.020 |
Why?
| | Pediatrics | 1 | 2017 | 1076 | 0.020 |
Why?
| | Walking | 1 | 2014 | 535 | 0.020 |
Why?
| | Erythrocytes | 1 | 1995 | 711 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2015 | 2497 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2486 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2011 | 209 | 0.020 |
Why?
| | Pneumonia | 1 | 2015 | 644 | 0.020 |
Why?
| | Sepsis | 1 | 1995 | 610 | 0.020 |
Why?
| | Databases, Factual | 1 | 2014 | 1404 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 622 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1494 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1873 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1656 | 0.020 |
Why?
| | Chelation Therapy | 1 | 2007 | 10 | 0.020 |
Why?
| | Infant | 3 | 2014 | 9576 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 250 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2057 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2738 | 0.020 |
Why?
| | Calcinosis | 1 | 2008 | 238 | 0.020 |
Why?
| | Health Personnel | 1 | 2013 | 726 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 150 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2016 | 1737 | 0.020 |
Why?
| | Health Services | 1 | 2007 | 116 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2044 | 0.020 |
Why?
| | Mental Disorders | 1 | 1994 | 1091 | 0.010 |
Why?
| | Models, Biological | 1 | 2013 | 1818 | 0.010 |
Why?
| | Program Development | 1 | 2007 | 362 | 0.010 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 1995 | 135 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 790 | 0.010 |
Why?
| | Isotope Labeling | 2 | 1995 | 79 | 0.010 |
Why?
| | Critical Illness | 1 | 2010 | 835 | 0.010 |
Why?
| | Academic Medical Centers | 1 | 2007 | 512 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2089 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2007 | 384 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2007 | 799 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2008 | 1159 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2008 | 1225 | 0.010 |
Why?
| | Physicians | 1 | 2008 | 929 | 0.010 |
Why?
| | Delivery of Health Care | 1 | 2007 | 961 | 0.010 |
Why?
| | Liver Function Tests | 1 | 1996 | 109 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 207 | 0.010 |
Why?
| | Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| | 4-Aminobenzoic Acid | 1 | 1995 | 8 | 0.010 |
Why?
| | Vacuoles | 1 | 1995 | 40 | 0.010 |
Why?
| | Lactobacillus | 1 | 1995 | 29 | 0.010 |
Why?
| | Radionuclide Imaging | 1 | 1995 | 118 | 0.010 |
Why?
| | Reference Standards | 1 | 1995 | 184 | 0.010 |
Why?
| | Carbon Isotopes | 1 | 1995 | 141 | 0.010 |
Why?
| | Aspartic Acid | 1 | 1994 | 81 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1994 | 81 | 0.010 |
Why?
| | Deuterium | 1 | 1994 | 99 | 0.010 |
Why?
| | Disease Susceptibility | 1 | 1995 | 350 | 0.010 |
Why?
| | Reference Values | 1 | 1994 | 804 | 0.010 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 219 | 0.010 |
Why?
| | Cattle | 1 | 1995 | 997 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1958 | 0.000 |
Why?
| | Brain | 1 | 1994 | 2790 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|